Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
REVIEW PAPER
Hypertrophic pachymeningitis as an important neurological complication of granulomatosis with polyangiitis
Submission date: 2018-09-04
Final revision date: 2018-10-07
Acceptance date: 2018-11-20
Online publication date: 2018-12-23
Publication date: 2018-12-23
Reumatologia 2018;56(6):399-405
KEYWORDS
TOPICS
Vasculitis - aetiology, pathogenesis, clinical features and treatmentDiagnostics and imaging in rheumatic diseases
ABSTRACT
Headache is a common symptom in patients with granulomatosis with polyangiitis (GPA) mainly due to chronic sinusitis or orbital disease. Meningeal involvement may thus remain unrecognized for a long time. This can lead to a significant delay in accurate diagnosis, serious local damage of the central nervous system and high relapse rates. New diagnostic techniques such as contrast MRI allow one to identify inflammation of the dura mater in the course of GPA more frequently. The objective of this article is to characterize hypertrophic pachymeningitis (HP) in patients with GPA and report diagnostic difficulties associated with this complication.
REFERENCES (35)
1.
Stone JH. Wegener`s Granulomatosis Etanercept Trial Research G. Limited versus severe Wegener’s granulomatosis: baseline data on patients in the Wegener’s granulomatosis etanercept trial. Arthritis Rheum 2003; 48: 2299-2309.
2.
de Groot K, Schmidt DK, Arlt AC, et al. Standardized neurologic evaluations of 128 patients with Wegener granulomatosis. Arch Neurol 2001; 58: 1215-1221.
3.
Anderson JM, Jamieson DG, Jefferson JM. Non-healing granuloma and the nervous system. Q J Med 1975; 44: 309-323.
4.
Nishino H, Rubino FA, DeRemee RA, et al. Neurological involvement in Wegener’s granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic. Ann Neurol 1993; 33: 4-9.
5.
Fragoulis GE, Lionaki S, Venetsanopoulu A, et al. Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study. Clin Rheumatol 2018; 37: 737-747.
6.
Reinhold-Keller E, de Groot K, Holl-Ulrich K. Severe CNS manifestations as the clinical hallmark in generalized Wegener’s granulomatosis consistently negative for anti-neutrophil cytoplasmic antibodies (ANCA). A report of 3 cases and a review of the literature. Clin Exp Rheum 2001; 9: 541-549.
7.
Higuera-Ortiz V, Reynoso A, Ruiz N, et al. Pachymeningitis in granulomatosis with polyangiitis: case series with earlier onset in younger patients and literature review. Clin Rheumatol 2017; 36: 919-924.
8.
Seror R, Mahr A, Ramanoelina J, et al. Central nervous system involvement in Wegener granulomatosis. Medicine 2006; 85: 54-65.
9.
David A, Drachman MD. Neurological complications of Wegener’s granulomatosis. Arch Neurol 1963; 8: 145-155.
10.
Sivakumar MR, Chandrakantan R. A rare case of stroke in Wegener’s granulomatosis. Cerebrovasc Dis 2002; 13: 143-144.
11.
Peng W, Wang X. Hypertrophic pachymeningitis and cerebral infarction resulting from ANCA-associated vasculitis. Neurol India 2012; 60: 424-426.
12.
Takei H, Komaba Y, Kitamura H. Aneurysmal sub-arachnoid hemorrhage in a patient with Wegener’s granulomatosis. J Clin Exp Nephrol 2004; 8: 274-278.
13.
Yokoseki A, Saji E, Arakawa M, et al. Hypertrophic pachymeningitis: significance of myeloperoxidase anti-neutrophil cytoplasmic antibody. Brain 2014; 137: 520-536.
14.
Bruggemann N, Gottschalk S, Holl-Ulrich K, et al. Cranial pachymeningitis: a rare neurological syndrome with heterogeneous aetiology. J Neurol Neurosurg Psychiatry 2010; 81: 294-298.
15.
Choi HA, Lee MJ, Chung CS. Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis. J Neurol 2017; 264: 724-732.
16.
Graf J. Central nervous system disease in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. Rheum Dis Clin North Am 2017; 43: 573-578.
17.
De Luna G, Terrier B, Kaminsky P, et al. Central nervous system involvement of granulomatosis with polyangiitis: clinical radiological presentation distinguishes different outcomes. Rheumatology (Oxford) 2015; 54: 424-432.
18.
Sakellariou GT, Kefala N. Pachymeningitis in granulomatosis with polyangiitis: a case report and a review of the literature. Case Rep Rheumatol 2013; 2013: 840984.
19.
Waliszewska-Prosół M, Dziadkowiak E, Budrewicz S, et al. Idopatyczny przerost opony twardej – opis przypadku. Pol Przegl Neurol 2015; 11: 72-76.
20.
Jang Y, Lee ST, Jung KH, et al. Rituximab Treatment for Idiopathic Hypertrophic Pachymeningitis. J Clin Neurol 2017; 13: 155-161.
21.
Kupersmith MJ, Martin V, Heller G, et al. Idiopathic hypertrophic pachymeningitis. Neurology 2004; 62: 686-694.
22.
Murphy JM, Gomez-Anson B, Gillard JH, et al. Wegener granulomatosis: MR imaging findings in brain and meninges. Radiology 1999; 213: 794-799.
23.
Provenzale JM, Allen NB. Wegener granulomatosis: CT and MR findings. AJNR Am J Neuroradiol 1996; 17: 785-792.
24.
Holle JU, Gross WL. Neurological involvement in Wegener’s granulomatosis. Curr Opin Rheumatol 2011; 23: 7-11.
25.
Di Comite G, Bozzolo EP, Praderio L, et al. Meningeal involvement in Wegener’s granulomatosis is associated with localized disease. Clin Exp Rheumatol 2006; 24 (Suppl 41): 60-64.
26.
Huang K, Xu Q, Zhan R, et al. Cerebral venous sinus thrombosis secondary to idiopathic hypertrophic cranial pachymeningitis: case report and review of literature. World Neurosurg 2017; 106: 1052.e13-1052.e21.
27.
Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. J Neurol 2015; 262: 258-267.
28.
Hoyle JC, Jablonski C, Newton HB. Neurosarcoidosis: clinical review of a disorder with challenging inpatient presentations and diagnostic considerations. Neurohospitalist 2014; 4: 94-101.
29.
Mekinian A, Maisonobe L, Boukari L, et al. Characteristics, outcome and treatments with cranial pachymeningitis: A multicenter French retrospective study of 60 patients. Medicine (Baltimore) 2018; 97: e11413.
30.
Yin LS, Kumar G, Vijayananthan A. Diffuse intracranial meningeal enhancement in Wegener’s granulomatosis – A rare finding. Eur J Radiol Extra 2008; 67: 5-8.
31.
Baptista B, Casian A, Gunawardena H, et al. Neurological Manifestations of IgG4-Related Disease. Curr Treat Options Neurol 2017; 19: 14.
32.
Popkirov S, Kowalski T, Schlegel U, et al. Immunoglobulin-G4-related hypertrophic pachymeningitis with anti-neutrophil cytoplasmic antibodies effectively treated with rituximab. J Clin Neurosci 2015; 22: 1038-1040.
33.
Arnaoutoglou MA, Xerras CG, Kalevrosoglou IK, et al. Headache Linked to Intracranial Hypertension and Hypertrophic Pachymeningitis as the Initial and Dominant Presentation of Granulomatosis With Polyangiitis. Case Report and Review of the Recent Literature. Headache 2018; 15: 1-7.
34.
Dash GK, Thomas B, Nair M, Radhakrishnan A. Clinico-radiological spectrum and outcome in idiopathic hypertrophic pachymeningitis. J Neurol Sci 2015; 350: 51-60.
35.
Costa C, Santiago T, Espirito-Santo J, et al. Pachymeningitis and cerebral granuloma in granulomatosis with polyangiitis: is rituximab a promising treatment option? Acta Reumatol Port 2017; 42: 82-87.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
